缬沙坦联合丹参注射液对糖尿病肾病患者微量尿白蛋白及血清C反应蛋白的影响

目的观察缬沙坦联合丹参注射液治疗早期糖尿病肾病（DN）的疗效。方法将212例DN患者随机分为对照组和治疗组，对照组102例，给予缬沙坦80mg／d；治疗组110例，在缬沙坦治疗的基础上给予丹参注射液20ml静脉滴注，每日1次，2周为1个疗程。每3个月给予1个疗程的治疗，共治疗18个月。观察治疗前后尿白蛋白排出量（UAE）和血清C反应蛋白（CRP）水平的变化。结果2组治疗后UAE均下降（P〈0．05，P〈0．01），且组间比较差异有显著性（P〈0．01）。疗程结束后，治疗组血清CRP降低（P〈0．01）。对照组降低不明显（P〉0．05），组间比较差异有显著性（P〈0．01）。结论缬沙坦与丹参注射液联合应用可减少UAE、降低血清CRP水平，对早期糖尿病肾病有较好的肾脏保护作用。

The study of urinary albumin excretion and serum C-reactive protein on patients with diabetic nephropathy treated by Valsartan combined with Salvia injection

Objective To investigate the effect of Valsartan combined with Salvia Injection on the early Diabetic Nephropathy（DN）. Method 212 patients with DN were randomly divided into two groups： the control group and the treatment group. 102 patients in control group received Valsartan 80mg/per day, while 110 patients in treatment group received additional 20 ml Salvia Injection by intravenous injection. Both of two groups were treated for 18 months, once a day,two weeks for one course and one course every three months. The changes of Urinary Albumin Excretion（ UAE ）and serum C-reactive protein（CRP） level were observed before and after theraphy. Results After the treatment, the UAE of the both groups wasdecreased （ P 〈 0.05, P 〈 0.01 ） and there was significant difference （ P 〈 0.01 ） between two groups. The C RP in the treatment group decreased（P 〈0.01 ） ,while there was no change in the control group（P 〉0.05）. Significant difference between the two groups was found （ P 〈 0.01 ）. Conclusion Valsartan combined with Salvia Injection can reduce UAE and CRP level and has protective effects against early diabetic nephropathy.